Evogene Ltd. (NASDAQ:EVGN) Position Lessened by BNP Paribas Financial Markets

BNP Paribas Financial Markets lowered its position in Evogene Ltd. (NASDAQ:EVGN) by 87.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,200 shares of the biotechnology company’s stock after selling 88,191 shares during the quarter. BNP Paribas Financial Markets owned approximately 0.23% of Evogene worth $37,000 at the end of the most recent quarter.

Separately, Renaissance Investment Group LLC acquired a new stake in shares of Evogene during the 3rd quarter valued at about $31,000. Hedge funds and other institutional investors own 10.40% of the company’s stock.

Evogene Price Performance

Shares of NASDAQ:EVGN opened at $1.29 on Friday. The stock has a market capitalization of $6.92 million, a P/E ratio of -0.29 and a beta of 1.36. The business has a 50-day moving average of $1.88 and a two-hundred day moving average of $3.68. Evogene Ltd. has a fifty-two week low of $1.20 and a fifty-two week high of $10.40.

Wall Street Analyst Weigh In

A number of research firms recently commented on EVGN. Lake Street Capital dropped their price objective on Evogene from $30.00 to $12.00 and set a “buy” rating on the stock in a report on Friday, August 23rd. StockNews.com began coverage on shares of Evogene in a research note on Friday. They set a “sell” rating on the stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.